In this expert interview with our expert Michael Cork, a Professor of Dermatology at the University of Sheffield, discover the impact of atopic dermatitis and the unmet needs that remain in treating this disease with topical corticosteroids (TCS) and topical calcineurin inhibitors (TCI).
What impact can atopic dermatitis have on patients?
From interfering with work to negatively affecting sleep and mental health, see the profound impact on the lives of patients with atopic dermatitis.
What are the unmet needs in treating atopic dermatitis?
Learn about the significant unmet needs that remains in the treatment of atopic dermatitis in this short video with Professor Cork.
Current treatment options have limitations in terms of efficacy and adverse effects that can limit their use and the majority of patients surveyed with atopic dermatitis have described themselves as being not satisfied or only fairly satisfied with current available treatments1.
What affects treatment compliance in atopic dermatitis?
Find out about the reasons why steroids inspire fear in patients and the difficulty of using TCS treatment.
Steroid phobia has been observed in over 80% of patients and parents2,3, leading to an impact on treatment compliance3. Learn about the reasons why TCS treatment is associated with these fears.
What are the main limitations of topical corticosteroids and calcineurin inhibitors?
Discover the main limitations of using TCS and TCI for the treatment of atopic dermatitis.
Current guidelines recommend TCS and TCI for atopic dermatitis, but their safe and effective use requires adequate potency, sufficient dosage and correct application4. Their use is also limited by their treatment duration and adverse effects.
Meet our expert Professor Michael Cork
Michael Cork is a Professor of Dermatology in the Department of Infection, Immunity and Cardiovascular Disease at the University of Sheffield, United Kingdom.
- Paller AS, Mcalister RO, Doyle JJ, Jackson A. Perceptions of physicians and pediatric patients about atopic dermatitis, its impact, and its treatment. Clin Pediatr (Phila). 2002;41(5):323–332.
- Aubert-Wastiaux H, Moret L, Le Rhun A, Fontenoy AM, Nguyen JM, Leux C, et al. Topical corticosteroid phobia in atopic dermatitis: A study of its nature, origins and frequency. Br J Dermatol. 2011;165(4):808–814.
- Lee JY, Her Y, Kim CW, Kim SS. Topical corticosteroid phobia among parents of children with atopic eczema in Korea. Ann Dermatol. 2015;27(5):499–506.
- Wollenberg A, Barbarot S, Bieber T, Christen-Zaech S, Deleuran M, Fink-Wagner A, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatology Venereol. 2018;32(5):657–682.
This content has been developed independently of the sponsors who have had no editorial input into the content. Medthority received educational funding from the sponsor Pfizer in order to help provide its healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content.